Amphastar Pharmaceuticals, Inc. has disclosed a stock sale by its officer, William J. Peters, in a recent SEC filing. This transaction, which involved 16,000 shares, was valued at approximately $448,480. Such sales can impact the company's ownership structure and may influence investor sentiment.

Background

Amphastar Pharmaceuticals, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol AMPH. Amphastar has been active in the market, with several recent filings indicating ongoing corporate activities.

What the Filing Says

The filing, dated November 4, 2026, indicates that Peters sold the shares as part of the exercise of stock options. The filing notes, "The nature of acquisition transaction was the exercise of stock options." This suggests that the sale was planned and part of a broader compensation strategy.

Impact

This sale may affect shareholders and potential investors, as it reflects the actions of a key officer within the company. The transaction could lead to questions about the company's future direction and the motivations behind such sales by executives.

What's Next

The filing does not say what happens next.

Recent Transactions

In addition to the recent sale of 16,000 shares, William J. Peters has executed other transactions within the past three months. On August 7, 2026, he sold 8,180 shares for gross proceeds of approximately $183,886.40. Furthermore, on September 21, 2026, he sold an additional 4,139 shares, generating gross proceeds of about $103,475.00. These transactions indicate a pattern of share sales that may warrant further scrutiny from investors.

Stock Options and Compensation

The exercise of stock options by Peters, as noted in the filing, reflects a common practice among corporate executives to convert options into shares. This specific transaction occurred on the same date as the sale, November 4, 2026, which suggests that the sale was executed to realize gains from previously granted compensation. The filing indicates that the payment for the shares was made in cash, a typical method for such transactions.

Outstanding Shares

As of the filing date, Amphastar Pharmaceuticals had a total of 42,537,944 shares outstanding. This figure provides context for the scale of Peters' transactions in relation to the overall ownership structure of the company.

Broker Information

The sale was facilitated by UBS Financial Services, Inc., which is noted in the filing as the broker handling the transaction. This partnership with a well-known financial institution may lend credibility to the transaction process.

Conclusion

The filing does not provide insights into the motivations behind Peters' stock sales or how these transactions might affect his role within the company moving forward.